Details for Patent: 3,644,627

Summary for Patent: 3,644,627

Title:	Pharmaceutical compositions and methods for producing coronary dilation with 4 - aryl-1 4 - dihydropyridine derivatives
Abstract:	4-PHENYL-, 1,4-DIHYDROPYRIDINES OF THE FORMULA: 2,6-DI(R-),3,5-DI(R''-OOC-),4-(R"-PHENYL)-1,4-DIHYDRO PYRIDINE WHEREIN R IS HYDROGEN OR ALKYL OF 1 TO 3 CARBON ATOMS, R'' IS ALKYL OF 1 TO 4 CARBON ATOMS, AND R" IS HYDROGEN, HALOGEN, OR 1 OR 2 LOWER ALKYL, LOWER ALKOXY, NITRO, LOWER ACYLAMINO, LOWER ALKYLAMINO OR AMINO MOIETIES ARE PRODUCED BY REACTING BENZALDEHYDES OR SUBSTITUTED BENZALDEHYDES WITH ACYL FATTY ACID ESTERS OF THE FORMULA R-CO-CH2-COOR'' WHEREIN R AND R'' ARE AS ABOVE DEFINED WITH AMMONA. THESE 4-PHENYL-1,4-DIHYDROPRIDINES ARE USEFUL IN TREATING DISEASES OF THE CIRCULATION, ESPECIALLY THOSE CONCERNING CORONARIES. THEY ARE PARTICULARLY USEFUL IN THE TREATMENT OF ANGINA PECTORIS.
Inventor(s):	Friedrich Bossert, Wulf Vater
Assignee:	Bayer AG
Application Number:	US872442A
Patent Claim Types: see list of patent claims

What does US Patent 3,644,627 claim, and how does it position in the US drug patent landscape?

What is US Drug Patent 3,644,627?

US Patent 3,644,627 is a US drug patent with a defined set of claims covering a specific pharmaceutical invention.

However, the prompt does not include the patent’s claim text. Without the claim language, a complete, accurate scope analysis (claim-by-claim coverage, dependencies, key limitations, and design-around implications) cannot be produced.

---

What is the claim scope and what are the operative limitations?

The only provided information is: “The claims are:” with no claims following.

Because claim language is the sole basis for scope mapping in a patent landscape analysis (especially for US drug patents where small structural or functional limitations can swing infringement outcomes), this cannot be analyzed to an actionable standard without the actual claim text.

---

How does US 3,644,627 sit in the US patent landscape?

A useful landscape view depends on at least one of the following:

• the inventive subject matter (active ingredient, salt/form, formulation, prodrug, method of treatment, dosing regimen) and
• the independent claim(s) that define the enforceable boundary.

Those elements cannot be derived from the patent number alone in a way that produces a precise and complete landscape assessment consistent with professional patent analysis.

---

Key Takeaways

• The requested scope and claims analysis cannot be completed without the actual claim text for US 3,644,627.
• A credible US drug patent landscape mapping requires the claim-defined invention type (compound vs. composition vs. method) and the exact limitations in the independent claims.
• With no claim language supplied, the analysis would not meet an actionable standard for R&D or investment decisions.

---

FAQs

1. Can you analyze claim scope without the claim text?
   No. Claim scope is determined by the exact words, structure, and dependencies in the patent claims.

2. Can you infer scope from only the patent number?
   Not to the level required for infringement and landscape decisions, because the operative limitations sit inside the claim language.

3. What does a “scope and claims” analysis normally include?
   Independent-claim elements, dependent-claim add-ons, claim construction hotspots, and likely design-around vectors.

4. What drives landscape positioning for US drug patents?
   Whether the claims cover active ingredient, salt/form, formulation, or method-of-use, and how those claims overlap with contemporaneous filings.

5. What can be done next to enable this analysis?
   Provide the claim text (at least independent claims and key dependent claims).

---

References

[1] No sources were cited because the claim text and/or patent document content for US 3,644,627 was not provided in the prompt.

Drugs Protected by US Patent 3,644,627

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 3,644,627

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Belgium	712483
Germany	1670827
France	7849
United Kingdom	1173862